Close

Novel Ovarian Cancer Treatment By GSK Approved In Singapore

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

The oral, once-daily Zejula (niraparib) tablet, a first-line and recurrent upkeep care for women with advanced epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in full or partial remission after platinum-based chemotherapy, has been approved by the Health Sciences Authority, according to a statement from GlaxoSmithKline (GSK) Singapore.

Regardless of whether a patient has a BRCA mutation, Zejula is now the only poly (ADP-ribose) polymerase (PARP) inhibitor licenced in Singapore to be used as a single therapy for patients with advanced and recurrent ovarian cancer.

As of March 2022, Zejula is accessible for the first ovarian cancer (PRIMA) in 44 nations and 2 Special Administration Regions. Zejula is also being tested against a variety of tumour types and in combination with a number of different treatments. Notably, it is now undergoing testing in a Phase III clinical research called ZEST to examine its potential for treating individuals with breast cancers that have the specialised treatment needs of triple-negative breast cancer (TNBC) or BRCAm HER2- breast cancer.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back